Jeffrey Enejosa

机构：Eli Lilly (United States)

发表论文 54 篇 · 总被引 3414 次 · h-index 20

代表论文

• Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis (2020 · New England Journal of Medicine · 被引 308)
• Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (2020 · Annals of the Rheumatic Diseases · 被引 238)
• Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response (2019 · Annals of the Rheumatic Diseases · 被引 179)
• Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program (2021 · Drug Safety · 被引 44)
• Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE (2021 · Lara D. Veeken · 被引 33)
• Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy (2021 · International Journal of Rheumatic Diseases · 被引 23)